The Artificial Pancreas in Very Young Children With T1D
NCT ID: NCT03784027
Last Updated: 2025-03-27
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
81 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-05-01
Study Completion Date
2022-10-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme and JDRF. It evaluates the use of the Artificial Pancreas (closed loop system) in very young children with type 1 diabetes (T1D) aged 1-7 years. This outcome study aims to determine whether 24/7 automated closed loop glucose control improves time in range compared to sensor augmented pump therapy. An extension phase will evaluate the effect of long-term home use of the 24/7 automated hybrid closed loop insulin delivery system on glucose control (UK sites only).
The study employs an open-label, multi-centre, multi-national, randomized, two-period, crossover design. Participants undergo a 2-4 week run-in period, followed by two 16-week treatment periods (one for each therapy) separated by a 1-4 week washout. The order of treatments is randomized. Up to 80 young children (with a target of 72 randomized subjects) on insulin pump therapy will be recruited from paediatric outpatient diabetes clinics.
Before using the study devices, participants and their parents/guardians receive training on the safe use of the study pump, continuous glucose monitoring (CGM) device, and hybrid closed loop system. Nursery or school carers may also be trained if needed. During the closed loop arm, subjects use the system for 16 weeks under free-living conditions at home and in nursery/school without remote monitoring. In the control arm, subjects use sensor augmented pump therapy for 16 weeks under similar conditions, with regular contact and 24/7 telephone support from the study team.
The primary endpoint is the time spent in the target glucose range (3.9-10.0 mmol/l) as recorded by CGM. Secondary outcomes include the time spent with glucose levels above and below target and other CGM metrics. Safety assessments include the frequency and severity of hypoglycaemic episodes and diabetic ketoacidosis (DKA). In the extension phase, participants have follow-up contacts every 3 months, with the primary endpoint measured over 18 months from the end of the primary phase and compared to sensor augmented pump therapy during that phase. Secondary outcomes, safety, and utility will be assessed similarly.
The study employs an open-label, multi-centre, multi-national, randomized, two-period, crossover design. Participants undergo a 2-4 week run-in period, followed by two 16-week treatment periods (one for each therapy) separated by a 1-4 week washout. The order of treatments is randomized. Up to 80 young children (with a target of 72 randomized subjects) on insulin pump therapy will be recruited from paediatric outpatient diabetes clinics.
Before using the study devices, participants and their parents/guardians receive training on the safe use of the study pump, continuous glucose monitoring (CGM) device, and hybrid closed loop system. Nursery or school carers may also be trained if needed. During the closed loop arm, subjects use the system for 16 weeks under free-living conditions at home and in nursery/school without remote monitoring. In the control arm, subjects use sensor augmented pump therapy for 16 weeks under similar conditions, with regular contact and 24/7 telephone support from the study team.
The primary endpoint is the time spent in the target glucose range (3.9-10.0 mmol/l) as recorded by CGM. Secondary outcomes include the time spent with glucose levels above and below target and other CGM metrics. Safety assessments include the frequency and severity of hypoglycaemic episodes and diabetic ketoacidosis (DKA). In the extension phase, participants have follow-up contacts every 3 months, with the primary endpoint measured over 18 months from the end of the primary phase and compared to sensor augmented pump therapy during that phase. Secondary outcomes, safety, and utility will be assessed similarly.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01)
NCT03101865
Type 1 Diabetes Mellitus
COMPLETED
NA
Closed Loop From Onset in Type 1 Diabetes
NCT02871089
Diabetes Mellitus
Type 1 Diabetes
ACTIVE_NOT_RECRUITING
NA
Artificial Pancreas in Pediatric Patients (PEDarPAN)
NCT02620878
Type 1 Diabetes
COMPLETED
NA
The Performance of an Artificial Pancreas at Home in People With Type 1 Diabetes
NCT02040571
Type 1 Diabetes
COMPLETED
NA
Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes
NCT01074801
Type 1 Diabetes
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Purpose of clinical trial:
To determine whether 24/7 automated hybrid closed loop will improve glucose control as measured by time within the target range compared with sensor augmented pump therapy in very young children with T1D.
Study objectives:
The study objective is to evaluate the safety, efficacy and utility of automated hybrid closed loop glucose control in very young children with type 1 diabetes.
1. EFFICACY: The objective is to assess the ability of a hybrid closed loop system to maintain CGM glucose levels within the target range of 3.9 to 10 mmol/l (70 to 180 mg/dl) in comparison with sensor augmented pump therapy in very young children with type 1 diabetes.
2. SAFETY: The objective is to evaluate the safety of closed loop glucose control compared with sensor augmented pump therapy in terms of episodes and severity of hypoglycaemia, frequency of diabetic ketoacidosis (DKA) and nature and severity of other adverse events.
3. UTILITY: The objective is to determine the acceptability and duration of use of the closed loop system in this population.
4. HUMAN FACTORS: The objective is to assess emotional and behavioural characteristics of participants and parents/guardians and their response to the closed loop system and clinical trial using validated surveys and semi-structured qualitative interviews.
5. HEALTH ECONOMICS: The objective is to perform a cost utility analysis to inform reimbursement decision-making.
Participating clinical centres:
1. Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
2. Leeds Teaching Hospitals NHS Trust, Leeds, UK
3. DECCP, Centre Hospitalier de Luxembourg, Grand Duché de Luxembourg
4. University of Leipzig, Leipzig, Germany
5. Medical University of Graz, Graz, Austria
6. Medical University of Innsbruck, Innsbruck, Austria
7. Medical University of Vienna, Vienna, Austria
Sample Size:
72 participants randomised (8-12 participants per centre). At the primary phase final visit, participants (UK sites only) on sensor-augmented pump therapy as their standard clinical care will be invited to participate in an extension phase of closed loop therapy for a further 18 months.
Maximum duration of study for a subject: 11 months (primary phase). 29 months for participants (UK sites only) opting to participate in 18-month extension phase.
Recruitment:
The subjects will be recruited through paediatric diabetes outpatient clinics at participating clinical centres (see above). Enrolment will target up to 80 (aiming for 8-12 participants per centre) to allow for dropouts during run-in.
Participants (UK sites only) completing the primary phase, who are on sensor-augmented pump therapy as their standard clinical care, will be invited to participate in the extension phase.
Consent:
Written informed consent will be obtained from all parents/guardians and written assent from older children before any study related activities.
Additional written consent will be obtained for the extension phase from all parents/guardians.
Baseline Assessment:
Eligible subjects will undergo a baseline assessment including a blood sample for the measurement of HbA1c. Questionnaires will be completed by parents/guardians.
Pre-Study Training and Run-in:
Training sessions on the use of the study CGM and insulin pump will be provided by the research team. During a 2-4 week run-in period, subjects will use study CGM and insulin pump. For compliance and to assess the ability of the subject to use the study devices safely, at least 8 days of CGM data need to be recorded and safe use of study insulin pump demonstrated during the last 14 days of run-in period. The CGM data will also be used to assess baseline glucose control and may be used for treatment optimization as necessary.
Competency Assessment:
Competency on the use of study insulin pump and study CGM will be evaluated using a competency assessment tool developed by the research team. Training may be repeated if required.
Randomisation:
Eligible subjects will be randomised using randomisation software to the initial use of automated hybrid closed loop glucose system or to sensor augmented pump therapy for 16 weeks with a 1 to 4 week washout period before crossing over to the other study arm.
Automated day and night closed loop insulin delivery (intervention arm)
Participants in the closed loop arm and their caregivers will receive an additional training session covering the use of the closed loop system provided by the research team prior to starting closed loop insulin delivery. During this 1-2 hour session, parents/guardians will operate the system under the supervision of the clinical research team. Competency on the use of closed loop system will be evaluated. Thereafter, subjects and their parents/guardians will use the hybrid closed loop system for 16 weeks at home.
Crossover Assessment:
At the end of the first study arm, a blood sample for the measurement of HbA1c will be taken and weight and height will be measured. Validated surveys evaluating the impact of the devices employed on quality of life, psychosocial function, diabetes management and treatment satisfaction will be completed.
Parents/guardians will be invited to be interviewed to gather feedback on and reactions to their current treatment, the clinical trial, and quality of life changes.
Sensor augmented pump therapy (control arm):
Participants in the sensor augmented pump therapy arm and their caregivers will receive refresher training on key aspects of insulin pump therapy and CGM use.
Subjects and their parents/guardians will continue using sensor augmented pump therapy for 16 weeks at home.
Study contacts:
Participants will be contacted 24h after starting each study arm to ensure there are no concerns regarding the study devices. In between study visits, participants will be contacted by the study team (email/phone) once monthly and 3-monthly in the extension phase, in order to record any adverse events, device deficiencies, and changes in insulin settings, other medical conditions and/or medication.
In case of any problems related to the technical device or diabetes management such as hypo- or hyperglycaemia, subjects will be able to contact a 24-hour telephone helpline to the local research team at any time. The local research team will have access to central 24 hour advice on technical issues.
End of study assessments (primary phase):
A blood sample will be taken for measurement of HbA1c at the end of the study. Height and weight will be recorded. Study devices will be downloaded and returned. Participants will resume usual care using their pre-study insulin pump. Validated surveys evaluating the impact of the devices employed on quality of life, psychosocial function and diabetes management and treatment satisfaction will be completed.
Parents/guardians will be invited to participate in a sleep sub-study prior to the final visit (UK \& Luxembourg only).
Parents/guardians will be invited to be interviewed to gather feedback on and reactions to their current treatment, the clinical trial, and quality of life changes.
Extension Phase (UK sites only):
Follow up contacts will be conducted 3-monthly, in line with routine clinic visits, including recording of adverse events, medical history, insulin requirements and HbA1c.
After 18 months from the end of the primary phase, parents/guardians will complete validated questionnaires evaluating the impact of the technology on quality of life, diabetes management, sleep quality and fear of hypoglycaemia. Height and weight will be measured. A blood sample will be taken for measurement of HbA1c at the end of the extension phase
Procedures for safety monitoring during trial:
Standard operating procedures for monitoring and reporting of all adverse events will be in place, including serious adverse events (SAE), serious adverse device effects (SADE) and specific adverse events (AE) such as severe hypoglycaemia.
A data safety and monitoring board (DSMB) will be informed of all serious adverse events and any unanticipated serious adverse device effects that occur during the study and will review compiled adverse event data at periodic intervals.
Criteria for withdrawal of subjects on safety grounds:
A subject/guardian may terminate participation in the study at any time without necessarily giving a reason and without any personal disadvantage. An investigator can stop the participation of a subject after consideration of the benefit/risk ratio. Possible reasons are:
* Serious adverse events
* Non-compliance
* Serious protocol violation
* Decision by the investigator, or the sponsor, that termination is in the subject's best medical interest
* Allergic reaction to insulin
To determine whether 24/7 automated hybrid closed loop will improve glucose control as measured by time within the target range compared with sensor augmented pump therapy in very young children with T1D.
Study objectives:
The study objective is to evaluate the safety, efficacy and utility of automated hybrid closed loop glucose control in very young children with type 1 diabetes.
1. EFFICACY: The objective is to assess the ability of a hybrid closed loop system to maintain CGM glucose levels within the target range of 3.9 to 10 mmol/l (70 to 180 mg/dl) in comparison with sensor augmented pump therapy in very young children with type 1 diabetes.
2. SAFETY: The objective is to evaluate the safety of closed loop glucose control compared with sensor augmented pump therapy in terms of episodes and severity of hypoglycaemia, frequency of diabetic ketoacidosis (DKA) and nature and severity of other adverse events.
3. UTILITY: The objective is to determine the acceptability and duration of use of the closed loop system in this population.
4. HUMAN FACTORS: The objective is to assess emotional and behavioural characteristics of participants and parents/guardians and their response to the closed loop system and clinical trial using validated surveys and semi-structured qualitative interviews.
5. HEALTH ECONOMICS: The objective is to perform a cost utility analysis to inform reimbursement decision-making.
Participating clinical centres:
1. Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
2. Leeds Teaching Hospitals NHS Trust, Leeds, UK
3. DECCP, Centre Hospitalier de Luxembourg, Grand Duché de Luxembourg
4. University of Leipzig, Leipzig, Germany
5. Medical University of Graz, Graz, Austria
6. Medical University of Innsbruck, Innsbruck, Austria
7. Medical University of Vienna, Vienna, Austria
Sample Size:
72 participants randomised (8-12 participants per centre). At the primary phase final visit, participants (UK sites only) on sensor-augmented pump therapy as their standard clinical care will be invited to participate in an extension phase of closed loop therapy for a further 18 months.
Maximum duration of study for a subject: 11 months (primary phase). 29 months for participants (UK sites only) opting to participate in 18-month extension phase.
Recruitment:
The subjects will be recruited through paediatric diabetes outpatient clinics at participating clinical centres (see above). Enrolment will target up to 80 (aiming for 8-12 participants per centre) to allow for dropouts during run-in.
Participants (UK sites only) completing the primary phase, who are on sensor-augmented pump therapy as their standard clinical care, will be invited to participate in the extension phase.
Consent:
Written informed consent will be obtained from all parents/guardians and written assent from older children before any study related activities.
Additional written consent will be obtained for the extension phase from all parents/guardians.
Baseline Assessment:
Eligible subjects will undergo a baseline assessment including a blood sample for the measurement of HbA1c. Questionnaires will be completed by parents/guardians.
Pre-Study Training and Run-in:
Training sessions on the use of the study CGM and insulin pump will be provided by the research team. During a 2-4 week run-in period, subjects will use study CGM and insulin pump. For compliance and to assess the ability of the subject to use the study devices safely, at least 8 days of CGM data need to be recorded and safe use of study insulin pump demonstrated during the last 14 days of run-in period. The CGM data will also be used to assess baseline glucose control and may be used for treatment optimization as necessary.
Competency Assessment:
Competency on the use of study insulin pump and study CGM will be evaluated using a competency assessment tool developed by the research team. Training may be repeated if required.
Randomisation:
Eligible subjects will be randomised using randomisation software to the initial use of automated hybrid closed loop glucose system or to sensor augmented pump therapy for 16 weeks with a 1 to 4 week washout period before crossing over to the other study arm.
Automated day and night closed loop insulin delivery (intervention arm)
Participants in the closed loop arm and their caregivers will receive an additional training session covering the use of the closed loop system provided by the research team prior to starting closed loop insulin delivery. During this 1-2 hour session, parents/guardians will operate the system under the supervision of the clinical research team. Competency on the use of closed loop system will be evaluated. Thereafter, subjects and their parents/guardians will use the hybrid closed loop system for 16 weeks at home.
Crossover Assessment:
At the end of the first study arm, a blood sample for the measurement of HbA1c will be taken and weight and height will be measured. Validated surveys evaluating the impact of the devices employed on quality of life, psychosocial function, diabetes management and treatment satisfaction will be completed.
Parents/guardians will be invited to be interviewed to gather feedback on and reactions to their current treatment, the clinical trial, and quality of life changes.
Sensor augmented pump therapy (control arm):
Participants in the sensor augmented pump therapy arm and their caregivers will receive refresher training on key aspects of insulin pump therapy and CGM use.
Subjects and their parents/guardians will continue using sensor augmented pump therapy for 16 weeks at home.
Study contacts:
Participants will be contacted 24h after starting each study arm to ensure there are no concerns regarding the study devices. In between study visits, participants will be contacted by the study team (email/phone) once monthly and 3-monthly in the extension phase, in order to record any adverse events, device deficiencies, and changes in insulin settings, other medical conditions and/or medication.
In case of any problems related to the technical device or diabetes management such as hypo- or hyperglycaemia, subjects will be able to contact a 24-hour telephone helpline to the local research team at any time. The local research team will have access to central 24 hour advice on technical issues.
End of study assessments (primary phase):
A blood sample will be taken for measurement of HbA1c at the end of the study. Height and weight will be recorded. Study devices will be downloaded and returned. Participants will resume usual care using their pre-study insulin pump. Validated surveys evaluating the impact of the devices employed on quality of life, psychosocial function and diabetes management and treatment satisfaction will be completed.
Parents/guardians will be invited to participate in a sleep sub-study prior to the final visit (UK \& Luxembourg only).
Parents/guardians will be invited to be interviewed to gather feedback on and reactions to their current treatment, the clinical trial, and quality of life changes.
Extension Phase (UK sites only):
Follow up contacts will be conducted 3-monthly, in line with routine clinic visits, including recording of adverse events, medical history, insulin requirements and HbA1c.
After 18 months from the end of the primary phase, parents/guardians will complete validated questionnaires evaluating the impact of the technology on quality of life, diabetes management, sleep quality and fear of hypoglycaemia. Height and weight will be measured. A blood sample will be taken for measurement of HbA1c at the end of the extension phase
Procedures for safety monitoring during trial:
Standard operating procedures for monitoring and reporting of all adverse events will be in place, including serious adverse events (SAE), serious adverse device effects (SADE) and specific adverse events (AE) such as severe hypoglycaemia.
A data safety and monitoring board (DSMB) will be informed of all serious adverse events and any unanticipated serious adverse device effects that occur during the study and will review compiled adverse event data at periodic intervals.
Criteria for withdrawal of subjects on safety grounds:
A subject/guardian may terminate participation in the study at any time without necessarily giving a reason and without any personal disadvantage. An investigator can stop the participation of a subject after consideration of the benefit/risk ratio. Possible reasons are:
* Serious adverse events
* Non-compliance
* Serious protocol violation
* Decision by the investigator, or the sponsor, that termination is in the subject's best medical interest
* Allergic reaction to insulin
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 1 Diabetes Mellitus
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Device: CamAPS FX
The automated closed loop system (CamAPS FX) will consist of:
* Dana RS insulin pump (Diabecare, Sooil, Seoul, South Korea)
* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor
* Cloud upload system to monitor CGM/insulin data.
The automated closed loop system (CamAPS FX) will consist of:
* Dana RS insulin pump (Diabecare, Sooil, Seoul, South Korea)
* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor
* Cloud upload system to monitor CGM/insulin data.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Automated closed loop insulin delivery (intervention arm)
Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 16 weeks.
Intervention: Device: CamAPS FX
Group Type
EXPERIMENTAL
CamAPS FX
Intervention Type
DEVICE
CamAPS FX closed loop system comprises:
* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)
* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor
* Cloud upload system to monitor CGM/insulin data
Sensor augmented pump therapy (control arm)
Sensor augmented pump therapy over 16 weeks.
Group Type
ACTIVE_COMPARATOR
Sensor augmented therapy
Intervention Type
OTHER
Study insulin pump and study CGM.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CamAPS FX
CamAPS FX closed loop system comprises:
* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)
* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor
* Cloud upload system to monitor CGM/insulin data
Intervention Type
DEVICE
Sensor augmented therapy
Study insulin pump and study CGM.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age between 1 and 7 years (inclusive) (Luxembourg and Austria)
2. Age between 2 and 7 years (inclusive) (Germany and UK)
3. Type 1 diabetes as defined by WHO for at least 6 months \[WHO definition: 'The aetiological type named type 1 encompasses the majority of cases which are primarily due to beta-cell destruction, and are prone to ketoacidosis. Type 1 includes those cases attributable to an autoimmune process, as well as those with beta-cell destruction for which neither an aetiology nor a pathogenesis is known (idiopathic). It does not include those forms of beta-cell destruction or failure to which specific causes can be assigned (e.g. cystic fibrosis, mitochondrial defects, etc.).'\]
4. Insulin pump user (with or without continuous glucose monitoring or flash glucose monitoring system) for at least 3 months, with subject/carer good knowledge of insulin self-adjustment as judged by the investigator
5. On sensor-augmented pump as standard clinical care (extension phase only)
6. Treated with rapid or ultra-rapid acting insulin analogue
7. Subject/carer is willing to perform regular finger-prick blood glucose monitoring, with at least 2 blood glucose measurements taken every day
8. Screening HbA1c ≤ 11% (97mmol/mol) on analysis from local laboratory
9. Willing to wear glucose sensor
10. Willing to wear closed loop system 24/7 during intervention arm
11. The subject/carer is willing to follow study specific instructions
12. The subject/carer is willing to upload pump and CGM data at regular intervals
2. Age between 2 and 7 years (inclusive) (Germany and UK)
3. Type 1 diabetes as defined by WHO for at least 6 months \[WHO definition: 'The aetiological type named type 1 encompasses the majority of cases which are primarily due to beta-cell destruction, and are prone to ketoacidosis. Type 1 includes those cases attributable to an autoimmune process, as well as those with beta-cell destruction for which neither an aetiology nor a pathogenesis is known (idiopathic). It does not include those forms of beta-cell destruction or failure to which specific causes can be assigned (e.g. cystic fibrosis, mitochondrial defects, etc.).'\]
4. Insulin pump user (with or without continuous glucose monitoring or flash glucose monitoring system) for at least 3 months, with subject/carer good knowledge of insulin self-adjustment as judged by the investigator
5. On sensor-augmented pump as standard clinical care (extension phase only)
6. Treated with rapid or ultra-rapid acting insulin analogue
7. Subject/carer is willing to perform regular finger-prick blood glucose monitoring, with at least 2 blood glucose measurements taken every day
8. Screening HbA1c ≤ 11% (97mmol/mol) on analysis from local laboratory
9. Willing to wear glucose sensor
10. Willing to wear closed loop system 24/7 during intervention arm
11. The subject/carer is willing to follow study specific instructions
12. The subject/carer is willing to upload pump and CGM data at regular intervals
Exclusion Criteria
1. Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
2. Untreated coeliac disease or thyroid disease based on local investigations prior to study enrolment
3. Current treatment with drugs known to interfere with glucose metabolism, e.g. systemic corticosteroids
4. Use of closed loop insulin delivery within the past 2 months
5. Known or suspected allergy to insulin
6. Carer's lack of reliable telephone facility for contact
7. Subject/carer's severe visual impairment
8. Subject/carer's severe hearing impairment
9. Medically documented allergy towards the adhesive (glue) of plasters or subject is unable to tolerate tape adhesive in the area of sensor placement
10. Serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) located in parts of the body which could potentially be used for localisation of the glucose sensor)
11. Sickle cell disease, haemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
12. Plan to receive red blood cell transfusion or erythropoietin over the course of study participation
13. Subject/carer not proficient in English (UK, Germany, Austria, Luxembourg) or German (Germany, Austria, Luxembourg) or French (Luxembourg)
14. Known microvascular diabetes complications (retinopathy, renal disease, neuropathy)
15. Eating disorders
16. Psychiatric diseases of the parents that would possibly interfere with the ability to comply to study procedures
17. Major needle phobia that would complicate to wear pump catheter and sensor
18. Congenital malformations that would interfere with diabetes treatment (e.g. congenital heart malformations, lung diseases, renal malformations)
19. Growth hormone deficiency
20. Combined Hypopituitarism
21. Down Syndrome (high risk for comorbidity with coeliac disease, autoimmune thyroiditis)
22. Cancer under treatment
23. Current participation in other interventional clinical trials
2. Untreated coeliac disease or thyroid disease based on local investigations prior to study enrolment
3. Current treatment with drugs known to interfere with glucose metabolism, e.g. systemic corticosteroids
4. Use of closed loop insulin delivery within the past 2 months
5. Known or suspected allergy to insulin
6. Carer's lack of reliable telephone facility for contact
7. Subject/carer's severe visual impairment
8. Subject/carer's severe hearing impairment
9. Medically documented allergy towards the adhesive (glue) of plasters or subject is unable to tolerate tape adhesive in the area of sensor placement
10. Serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) located in parts of the body which could potentially be used for localisation of the glucose sensor)
11. Sickle cell disease, haemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
12. Plan to receive red blood cell transfusion or erythropoietin over the course of study participation
13. Subject/carer not proficient in English (UK, Germany, Austria, Luxembourg) or German (Germany, Austria, Luxembourg) or French (Luxembourg)
14. Known microvascular diabetes complications (retinopathy, renal disease, neuropathy)
15. Eating disorders
16. Psychiatric diseases of the parents that would possibly interfere with the ability to comply to study procedures
17. Major needle phobia that would complicate to wear pump catheter and sensor
18. Congenital malformations that would interfere with diabetes treatment (e.g. congenital heart malformations, lung diseases, renal malformations)
19. Growth hormone deficiency
20. Combined Hypopituitarism
21. Down Syndrome (high risk for comorbidity with coeliac disease, autoimmune thyroiditis)
22. Cancer under treatment
23. Current participation in other interventional clinical trials
Minimum Eligible Age
1 Year
Maximum Eligible Age
7 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Commission
OTHER
Sponsor Role
collaborator
Cambridge University Hospitals NHS Foundation Trust
OTHER
Sponsor Role
collaborator
The Leeds Teaching Hospitals NHS Trust
OTHER
Sponsor Role
collaborator
University of Luxembourg
OTHER
Sponsor Role
collaborator
University of Leipzig
OTHER
Sponsor Role
collaborator
Medical University of Graz
OTHER
Sponsor Role
collaborator
Medical University Innsbruck
OTHER
Sponsor Role
collaborator
Medical University of Vienna
OTHER
Sponsor Role
collaborator
Jaeb Center for Health Research
OTHER
Sponsor Role
collaborator
University of Edinburgh
OTHER
Sponsor Role
collaborator
Stanford University
OTHER
Sponsor Role
collaborator
Glooko
INDUSTRY
Sponsor Role
collaborator
University of Cambridge
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Roman Hovorka
Study Director
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roman Hovorka
Role: STUDY_DIRECTOR
Wellcome Trust-MRC Institute of Metabolic Science University of Cambridge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Graz Department of Pediatrics and Adolescent Medicine
Graz, , Austria
Site Status
Medical University of Innsbruck Department of Pediatrics I
Innsbruck, , Austria
Site Status
Medical University of Vienna Department of Pediatrics
Vienna, , Austria
Site Status
University of Leipzig Division for Paediatric Diabetology
Leipzig, , Germany
Site Status
Clinique Pédiatrique de Luxembourg Centre Hospitalier de Luxembourg
Luxembourg, , Luxembourg
Site Status
University Department of Paediatrics
Cambridge, Cambridgeshire, United Kingdom
Site Status
Wellcome Trust-MRC Institute of Metabolic Science University of Cambridge
Cambridge, Cambridgeshire, United Kingdom
Site Status
St James's University Hospital
Leeds, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Austria
Germany
Luxembourg
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Elleri D, Allen JM, Tauschmann M, El-Khairi R, Benitez-Aguirre P, Acerini CL, Dunger DB, Hovorka R. Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3-6 years: comparison between diluted and standard insulin strength. BMJ Open Diabetes Res Care. 2014 Dec 11;2(1):e000040. doi: 10.1136/bmjdrc-2014-000040. eCollection 2014.
Reference Type
BACKGROUND
Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, Acerini CL, Dellweg S, Benesch C, Heinemann L, Mader JK, Holzer M, Kojzar H, Exall J, Yong J, Pichierri J, Barnard KD, Kollman C, Cheng P, Hindmarsh PC, Campbell FM, Arnolds S, Pieber TR, Evans ML, Dunger DB, Hovorka R. Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2129-2140. doi: 10.1056/NEJMoa1509351. Epub 2015 Sep 17.
Reference Type
BACKGROUND
Tauschmann M, Allen JM, Wilinska ME, Thabit H, Stewart Z, Cheng P, Kollman C, Acerini CL, Dunger DB, Hovorka R. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. Diabetes Care. 2016 Jul;39(7):1168-74. doi: 10.2337/dc15-2078. Epub 2016 Jan 6.
Reference Type
BACKGROUND
Tauschmann M, Allen JM, Wilinska ME, Thabit H, Acerini CL, Dunger DB, Hovorka R. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. Diabetes Care. 2016 Nov;39(11):2019-2025. doi: 10.2337/dc16-1094. Epub 2016 Sep 9.
Reference Type
BACKGROUND
Ware J, Allen JM, Boughton CK, Wilinska ME, Hartnell S, Thankamony A, de Beaufort C, Schierloh U, Frohlich-Reiterer E, Mader JK, Kapellen TM, Rami-Merhar B, Tauschmann M, Nagl K, Hofer SE, Campbell FM, Yong J, Hood KK, Lawton J, Roze S, Sibayan J, Bocchino LE, Kollman C, Hovorka R; KidsAP Consortium. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022 Jan 20;386(3):209-219. doi: 10.1056/NEJMoa2111673.
Reference Type
DERIVED
Fuchs J, Allen JM, Boughton CK, Wilinska ME, Thankamony A, de Beaufort C, Campbell F, Yong J, Froehlich-Reiterer E, Mader JK, Hofer SE, Kapellen TM, Rami-Merhar B, Tauschmann M, Hood K, Kimbell B, Lawton J, Roze S, Sibayan J, Cohen N, Hovorka R; KidsAP Consortium. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol. BMJ Open. 2021 Feb 12;11(2):e042790. doi: 10.1136/bmjopen-2020-042790.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KidsAP02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Closing the Loop in People with Type 1 Diabetes
NCT05653050
COMPLETED
NA
24/7 Closed-loop in Older Subjects With Type 1 Diabetes
NCT04025762
COMPLETED
NA
Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp
NCT02189694
COMPLETED
PHASE2
Efficacy of Automated Insulin Therapy Early Initiated After Diagnosis on Blood Glucose Control in Children and Adolescents With Type 1 Diabetes
NCT06283797
RECRUITING
NA
Closing the Loop 24/7 in Adolescents With Type 1 Diabetes
NCT01873066
COMPLETED
NA
Glycemic Outcomes and Safety With Minimed 780G System in Children With Type 1 Diabetes Aged 2-6 Years
NCT04949022
UNKNOWN
NA
Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children
NCT02509429
COMPLETED
PHASE2
Closed-loop in Adults With T2D Not Requiring Dialysis
NCT04701424
COMPLETED
NA
FASter Insulin in Closed-loop Technology in Children
NCT04759144
COMPLETED
NA
Efficacy of Closed-loop Insulin Therapy in Prepubertal Child in Free-life
NCT03739099
UNKNOWN
NA
Comparison of Two Management Systems in Patients With Type 1 Diabetes (Pediatric SmartHome)
NCT03815487
COMPLETED
NA
Closing the Loop in Children and Adolescents With Type 1 Diabetes in the Home Setting
NCT01778348
COMPLETED
PHASE2
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes
NCT02488616
WITHDRAWN
PHASE2
Closed-loop in Adults With T2D Requiring Dialysis
NCT04025775
COMPLETED
NA
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
NCT02105324
COMPLETED
NA
Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004)
NCT00977808
COMPLETED
NA
Portable Artificial Pancreas Applied for Youth and Adolescents
NCT05543850
COMPLETED
NA
Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)
NCT01472406
COMPLETED
EARLY_PHASE1
Closing the Loop in Youth With Type 1 Diabetes in the Home Setting
NCT01221467
COMPLETED
PHASE2
Closed-loop in Adults With Type 2 Diabetes
NCT06579404
RECRUITING
NA
Closing the Loop in Adults With Type 1 Diabetes
NCT00910767
COMPLETED
NA
Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes
NCT04545567
COMPLETED
NA
Simplified Meal Approach Using Hybrid Closed-loop Insulin Delivery in Youth and Young Adults With Type 1 Diabetes
NCT05481034
COMPLETED
NA
Closing the Loop in Adults With Type 1 Diabetes (CLEAR)
NCT04977908
COMPLETED
NA